Significant variables in decreasing importance for varietal clustering based on Random forest method. by Wilfried Chevalier (10521466)

Regression results of poverty level expressed by poverty population. by Fuwei Wang (721008)

Subjects:

The aging-induced decrease in the number of dendritic branches in neurons of the hippocampus and cerebral cortex was attenuated by the administration of GTDE. by Hui-Chuan Kuo (12368492)

Subjects:

Correlation coefficients and associated level of significance. by Ștefan Andrei Neştian (14755581)

Correlation coefficients and associated level of significance. by Ștefan Andrei Neştian (14755581)

Gut richness and diversity decrease significantly by week 5 of chemoradiotherapy. by Molly B. El Alam (10231830)

Vibriocidal activities were significantly decreased by depletion of IgM in serum. by Jae Seung Yang (701319)

The application of GTDE efficiently increased the D-gal induced decline in the expression levels of BDNE. by Hui-Chuan Kuo (12368492)

Subjects:

County-level geographical septile distribution for the first 12 statistically significant factors with at least one statistically significant coefficient ranked by decreasing ΔIC. by Yanan Long (11784717)

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

Mindfulness-based stress reduction interventions. by Xiaoli Liu (165371)

Subjects:

GTDE effectively reduced d-gal-induced oxidative stress and increased the expression levels of antioxidant proteins and BDNF. by Hui-Chuan Kuo (12368492)

Subjects:

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

Rotenone exposure decreases GSH level in porcine oocytes. by Geun Heo (14185618)

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects: